Daiichi Sankyo, in collaboration with Plan International Japan launched a project titled“Promotion of Cancer Prevention and Adolescent Health in Indonesia.”in April, 2025.
Jakarta, the capital city of Indonesia, faces significant public health challenges due to the high prevalence of non-communicable diseases, especially breast cancer and cervical cancer. In 2022, the incidence rates of these cancers were estimated at 16.2% and 9.0% respectively, and the mortality rates were 9.3% and 8.5%. These cancers are the leading causes of cancer-related deaths among women in Jakarta.
Despite the importance of cancer screenings, participation remains low. This is largely due to a lack of awareness about the importance of early detection, a fear of being diagnosed as cancer, and financial constraints. HPV vaccination coverage is also low, partly due to misconceptions about its safety and effectiveness.
Furthermore, Jakarta’s healthcare system faces challenges in integrating youth-friendly health services focused on Sexual and Reproductive Health and Rights (SRHR) and the prevention of non-communicable diseases. The shortage of trained healthcare personnel further exacerbates these issues.
Against this backdrop, the goal of this project is to address these challenges by raising community awareness, improving access to cancer screenings and vaccinations, and strengthening the capacity of healthcare workers.
Project overview:
- Region: Special Capital Region of Jakarta, Indonesia
- Activity summary:
1）Increase awareness of SRHR, NCD prevention, cancers risk, among 2,000 women, adolescents, young people, and parents/ caregivers
2）Provide cervical and breast cancer screenings
3）Improve integrated health services
- Duration: 3 years (April 2025 to March 2028)
- Collaborative partner: Plan International Japan*1
- *1Plan International is an international NGO that works in more than 80 countries to promote children’s rights and achieve a society free from poverty and discrimination.https://www.plan-international.jp/
As a pharmaceutical company with the purpose, to “contribute to the enrichment of quality of life around the world,” the Daiichi Sankyo Group is committed to resolving healthcare access issues in regions with limited healthcare infrastructure